We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?
Read MoreHide Full Article
Key Takeaways
Stryker expects Q2 revenue growth as deferred orders recover and new products support demand.
DXCM is projected to post double-digit revenue growth, backed by G7 15 Day adoption and CGM demand.
Baxter and Merit Medical face margin pressure from tariffs, costs and operational challenges.
The Zacks Medical - Products industry is expected to report another quarter of resilient revenue growth, supported by healthy procedure volumes, favorable demographic trends and continued investments by hospitals in advanced medical technologies.
However, investors are likely to focus less on demand and more on profitability, as manufacturers continue to navigate a challenging operating environment marked by tariffs, persistent cost inflation and higher logistics expenses. Rising prices of semiconductors, electronic components, metals and freight are expected to have kept pressure on gross margins, forcing companies to rely on pricing actions, productivity initiatives and supply-chain optimization to protect earnings.
Robust adoption of robotic-assisted surgery, electrophysiology, structural heart therapies, AI-enabled imaging, radiopharmaceuticals and digital health solutions must have continued to support premium product demand across hospitals and outpatient settings. Healthy hospital capital spending, expanding recurring revenue streams from services and software, and strong innovation pipelines are also likely to have provided stability.
Nevertheless, company-specific operational disruptions, product remediation efforts and selective weakness in certain end markets could have resulted in mixed earnings performances, with margin expansion being more challenging than revenue growth.
The Medical - Products industry is housed within the broader Zacks Medical sector. Per the latest Earnings Trends report, total Medical sector earnings are expected to decline 17.4% in the April-June quarter on 5.2% higher revenues
A few of the major companies from the Medical-Products industry are lined up to report their quarterly numbers in the coming days. Let's see how things might have shaped up for Stryker (SYK - Free Report) , Baxter International (BAX - Free Report) , DexCom (DXCM - Free Report) and Merit Medical Systems (MMSI - Free Report) prior to their announcements.
Our quantitative model predicts an earnings beat for a company if it has a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). This combination increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for SYK’s second-quarter 2026 revenues is pegged at $6.56 billion, indicating 8.9% growth year over year. Management anticipates second-quarter 2026 sales to improve sequentially as recovery of deferred orders starts following a disruption in the first quarter due to a cyber incident. New product launches, including Mako 4, Mako Shoulder, Mako RPS and Triathlon Gold, are expected to have supported customer interest.
The Zacks Consensus Estimate for second-quarter 2026 earnings has remained stable over the past 30 days at $3.46 per share. The consensus mark implies a 10.5% upside from the year-ago reported numbers. Stryker’s margins are expected to have improved sequentially with production normalization, although tariff-related costs and higher input prices might have continued to weigh on gross margin.
SYK is scheduled to report second-quarter 2026 results on July 30, after market close. Our proven model does not conclusively predict an earnings beat for SYK this time around, as it has an Earnings ESP of 0.00% and a Zacks Rank #3 at present.
The Zacks Consensus Estimate for BAX’s second-quarter 2026 revenues is currently pegged at $2.79 billion, which indicates a 0.6% decline from the year-ago figures. The Zacks Consensus Estimate for BAX’s second-quarter 2026 earnings has been revised downward by 1 cent over the past 30 days to 36 cents per share. The consensus mark for earnings implies a 39% downside from that recorded a year ago.
Baxter is expected to have delivered a modestly improved second-quarter sales, though earnings are likely to have been constrained by ongoing operational headwinds, inflationary cost pressures and the continued shipment hold on its Novum large-volume infusion pump. While end-market demand remained healthy across several businesses, execution-related challenges and difficult year-over-year comparisons are expected to have weighed on profitability.
BAX is scheduled to report second-quarter 2026 results on July 30, before market opens. Our proven model does not conclusively predict an earnings beat for BAX this time around, as it has an Earnings ESP of -0.99% and a Zacks Rank #4 (Sell) at present.
DexCom is expected to have delivered another quarter of healthy revenue growth, supported by continued demand for continuous glucose monitoring (CGM) systems, expanding reimbursement, and sustained adoption of its recently launched G7 15 Day platform. The quarterly performance is likely to have benefited from increasing physician awareness of broader reimbursement coverage and continued conversion of existing users to the G7 15 Day system. Margins are likely to have been supported by manufacturing efficiencies, normalized freight costs, supply-chain improvements, and the initial contribution from G7 15 Day. However, uncertainty around resin cost and fuel price must have remained.
The Zacks Consensus Estimate for DXCM’s second-quarter 2026 revenues is currently pegged at $1.3 billion, which indicates an 11.9% uptick from the year-ago reported numbers. The Zacks Consensus Estimate for DXCM’s second-quarter 2026 earnings has remained stable over the past 30 days at 61 cents per share. The consensus mark for earnings implies a 27.1% upside from the year-ago reported figure.
DXCM is scheduled to report second-quarter 2026 results on July 30, after market close. Our proven model does not conclusively predict an earnings beat for DexCom this time around, as it has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. It had an Earnings ESP of -1.36% and a Zacks Rank of 2 when we issued our second-quarter 2026 earnings preview.
Merit Medical Systems is expected to have delivered another quarter of steady revenue growth, supported by continued execution across its therapeutic portfolio, resilient demand for vascular intervention products, and incremental contributions from recent acquisitions. However, DualCap divestiture and ongoing tariff-related costs might have partially offset growth. The Zacks Consensus Estimate for MMSI’s second-quarter 2026 revenues is currently pegged at $404.7 billion, which indicates a 5.8% uptick from the year-ago reported numbers.
Therapeutic products are expected to have remained the primary growth engine, led by sustained momentum in cardiac therapies, endoscopy and oncology. Endoscopy should have continued to benefit from strong adoption of the C2 CryoBalloon system and the rollout of the Resilience esophageal stent, while oncology growth is likely to have been aided by the early contribution from View Point Medical and continued demand for the SCOUT platform.
Foundational products are also expected to post healthy growth, supported by vascular intervention and access products. Procedural solutions sales are likely to have been hurt by the continued impact of the DualCap divestiture. OEM performance might have improved sequentially after first-quarter inventory destocking and weaker-than-expected customer orders, with management indicating confidence in a return to mid-single-digit growth.
Margins are expected to have remained under pressure from tariffs, freight costs and broader geopolitical uncertainties. However, adjusted earnings are likely to have been supported by improving operating leverage, healthy cash generation and continued execution of the company's Continued Growth Initiatives program.
The Zacks Consensus Estimate for MMSI’s second-quarter 2026 earnings has remained stable over the past 30 days at 96 cents per share. The consensus mark for earnings implies a 5% downside from the year-ago figures.
MMSI is scheduled to report second-quarter 2026 results on July 30, after market close. Our proven model does not conclusively predict an earnings beat for Merit Medical this time around, as it has an Earnings ESP of 0.00% and a Zacks Rank of 4 at present.
Merit Medical Systems, Inc. Price and EPS Surprise
View the Zacks #1 Rank List
Image: Shutterstock
Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?
Key Takeaways
The Zacks Medical - Products industry is expected to report another quarter of resilient revenue growth, supported by healthy procedure volumes, favorable demographic trends and continued investments by hospitals in advanced medical technologies.
However, investors are likely to focus less on demand and more on profitability, as manufacturers continue to navigate a challenging operating environment marked by tariffs, persistent cost inflation and higher logistics expenses. Rising prices of semiconductors, electronic components, metals and freight are expected to have kept pressure on gross margins, forcing companies to rely on pricing actions, productivity initiatives and supply-chain optimization to protect earnings.
Robust adoption of robotic-assisted surgery, electrophysiology, structural heart therapies, AI-enabled imaging, radiopharmaceuticals and digital health solutions must have continued to support premium product demand across hospitals and outpatient settings. Healthy hospital capital spending, expanding recurring revenue streams from services and software, and strong innovation pipelines are also likely to have provided stability.
Nevertheless, company-specific operational disruptions, product remediation efforts and selective weakness in certain end markets could have resulted in mixed earnings performances, with margin expansion being more challenging than revenue growth.
The Medical - Products industry is housed within the broader Zacks Medical sector. Per the latest Earnings Trends report, total Medical sector earnings are expected to decline 17.4% in the April-June quarter on 5.2% higher revenues
A few of the major companies from the Medical-Products industry are lined up to report their quarterly numbers in the coming days. Let's see how things might have shaped up for Stryker (SYK - Free Report) , Baxter International (BAX - Free Report) , DexCom (DXCM - Free Report) and Merit Medical Systems (MMSI - Free Report) prior to their announcements.
Our quantitative model predicts an earnings beat for a company if it has a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). This combination increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Let’s delve deeper.
Stryker
The Zacks Consensus Estimate for SYK’s second-quarter 2026 revenues is pegged at $6.56 billion, indicating 8.9% growth year over year. Management anticipates second-quarter 2026 sales to improve sequentially as recovery of deferred orders starts following a disruption in the first quarter due to a cyber incident. New product launches, including Mako 4, Mako Shoulder, Mako RPS and Triathlon Gold, are expected to have supported customer interest.
The Zacks Consensus Estimate for second-quarter 2026 earnings has remained stable over the past 30 days at $3.46 per share. The consensus mark implies a 10.5% upside from the year-ago reported numbers. Stryker’s margins are expected to have improved sequentially with production normalization, although tariff-related costs and higher input prices might have continued to weigh on gross margin.
SYK is scheduled to report second-quarter 2026 results on July 30, after market close. Our proven model does not conclusively predict an earnings beat for SYK this time around, as it has an Earnings ESP of 0.00% and a Zacks Rank #3 at present.
Stryker Corporation Price and EPS Surprise
Stryker Corporation price-eps-surprise | Stryker Corporation Quote
Baxter International
The Zacks Consensus Estimate for BAX’s second-quarter 2026 revenues is currently pegged at $2.79 billion, which indicates a 0.6% decline from the year-ago figures. The Zacks Consensus Estimate for BAX’s second-quarter 2026 earnings has been revised downward by 1 cent over the past 30 days to 36 cents per share. The consensus mark for earnings implies a 39% downside from that recorded a year ago.
Baxter is expected to have delivered a modestly improved second-quarter sales, though earnings are likely to have been constrained by ongoing operational headwinds, inflationary cost pressures and the continued shipment hold on its Novum large-volume infusion pump. While end-market demand remained healthy across several businesses, execution-related challenges and difficult year-over-year comparisons are expected to have weighed on profitability.
BAX is scheduled to report second-quarter 2026 results on July 30, before market opens. Our proven model does not conclusively predict an earnings beat for BAX this time around, as it has an Earnings ESP of -0.99% and a Zacks Rank #4 (Sell) at present.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. price-eps-surprise | Baxter International Inc. Quote
DexCom
DexCom is expected to have delivered another quarter of healthy revenue growth, supported by continued demand for continuous glucose monitoring (CGM) systems, expanding reimbursement, and sustained adoption of its recently launched G7 15 Day platform. The quarterly performance is likely to have benefited from increasing physician awareness of broader reimbursement coverage and continued conversion of existing users to the G7 15 Day system. Margins are likely to have been supported by manufacturing efficiencies, normalized freight costs, supply-chain improvements, and the initial contribution from G7 15 Day. However, uncertainty around resin cost and fuel price must have remained.
The Zacks Consensus Estimate for DXCM’s second-quarter 2026 revenues is currently pegged at $1.3 billion, which indicates an 11.9% uptick from the year-ago reported numbers. The Zacks Consensus Estimate for DXCM’s second-quarter 2026 earnings has remained stable over the past 30 days at 61 cents per share. The consensus mark for earnings implies a 27.1% upside from the year-ago reported figure.
DXCM is scheduled to report second-quarter 2026 results on July 30, after market close. Our proven model does not conclusively predict an earnings beat for DexCom this time around, as it has an Earnings ESP of 0.00% and a Zacks Rank #2 at present. It had an Earnings ESP of -1.36% and a Zacks Rank of 2 when we issued our second-quarter 2026 earnings preview.
DexCom, Inc. Price and EPS Surprise
DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote
Merit Medical Systems
Merit Medical Systems is expected to have delivered another quarter of steady revenue growth, supported by continued execution across its therapeutic portfolio, resilient demand for vascular intervention products, and incremental contributions from recent acquisitions. However, DualCap divestiture and ongoing tariff-related costs might have partially offset growth. The Zacks Consensus Estimate for MMSI’s second-quarter 2026 revenues is currently pegged at $404.7 billion, which indicates a 5.8% uptick from the year-ago reported numbers.
Therapeutic products are expected to have remained the primary growth engine, led by sustained momentum in cardiac therapies, endoscopy and oncology. Endoscopy should have continued to benefit from strong adoption of the C2 CryoBalloon system and the rollout of the Resilience esophageal stent, while oncology growth is likely to have been aided by the early contribution from View Point Medical and continued demand for the SCOUT platform.
Foundational products are also expected to post healthy growth, supported by vascular intervention and access products. Procedural solutions sales are likely to have been hurt by the continued impact of the DualCap divestiture. OEM performance might have improved sequentially after first-quarter inventory destocking and weaker-than-expected customer orders, with management indicating confidence in a return to mid-single-digit growth.
Margins are expected to have remained under pressure from tariffs, freight costs and broader geopolitical uncertainties. However, adjusted earnings are likely to have been supported by improving operating leverage, healthy cash generation and continued execution of the company's Continued Growth Initiatives program.
The Zacks Consensus Estimate for MMSI’s second-quarter 2026 earnings has remained stable over the past 30 days at 96 cents per share. The consensus mark for earnings implies a 5% downside from the year-ago figures.
MMSI is scheduled to report second-quarter 2026 results on July 30, after market close. Our proven model does not conclusively predict an earnings beat for Merit Medical this time around, as it has an Earnings ESP of 0.00% and a Zacks Rank of 4 at present.
Merit Medical Systems, Inc. Price and EPS Surprise
Merit Medical Systems, Inc. price-eps-surprise | Merit Medical Systems, Inc. Quote